Source-grounded facts extracted from Arcellx, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Thomas Kennedy was appointed as General Counsel at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Keeley Cain Wettan was appointed as Chief Financial Officer at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Andrew D. Dickinson was appointed as Chief Executive Officer at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Thomas Kennedy was appointed as Director at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Keeley Cain Wettan was appointed as Director at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Andrew D. Dickinson was appointed as Director at Arcellx, Inc..
“the directors and officers of Purchaser as of immediately prior to the Effective Time, which consisted of Andrew D. Dickinson, Keeley Cain Wettan, and Thomas Kennedy, became the directors and officers of the Company.”
Rami Elghandour resigned as Chief Executive Officer at Arcellx, Inc..
“each officer of the Company resigned and ceased to be an officer of the Company as of the Effective Time.”
Kristin Myers resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Andrew Galligan resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Jill Carroll resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Ali Behbahani resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Olivia Ware resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Kavita Patel resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
David Lubner resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Rami Elghandour resigned as Director at Arcellx, Inc..
“Rami Elghandour, David Lubner, Kavita Patel, Olivia Ware, Ali Behbahani, Jill Carroll, Andrew Galligan, and Kristin Myers, being all of the directors of the Company immediately prior to the Effective Time, resigned and ceased to be directors of the Company as of the Effective Time.”
Arcellx, Inc. entered into Agreement and Plan of Merger with Gilead Sciences, Inc. (effective 2026-02-22).
“On February 22, 2026, Arcellx, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Gilead Sciences, Inc., a Delaware corporation (“ Parent ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).”
Kristin Myers was appointed as Director at Arcellx, Inc..
“On March 18, 2025, the Board appointed Kristin Myers to fill one of the two vacancies on the Board, effective March 18, 2025, as a Class III director”
Andrew Galligan was appointed as Director at Arcellx, Inc..
“On March 18, 2025, the Board appointed Andrew Galligan to fill one of the two vacancies on the Board, effective March 18, 2025, as a Class I director”
Derek Yoon resigned as Director at Arcellx, Inc..
“On March 17, 2025, Arcellx, Inc. (the “Company”) was notified by Derek Yoon that he intended to resign from the Company’s board of directors (the “Board”) and from the Board committees on which he served.”
Arcellx, Inc. reported for the first quarter ended March 31, 2024 results: revenue $39.3 million, net income Net loss was $7.2 million.
“million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue were $39.3 million and $17.9 million for the quarters ended March 31, 2024 and 2023, respectively, an increase of $21.4 million. This increase was primarily driven by changes in estimated”
Arcellx, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“On March 8, 2024, the Board, upon the recommendation of the Audit Committee, approved the engagement of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, subject to PwC’s customary client acceptance procedures and the execution of an engagement letter.”
Arcellx, Inc. dismissed Ernst & Young LLP as its auditor.
“On March 8, 2024, the Board of Directors (the “Board”) of Arcellx, Inc. (the “Company”), upon the recommendation of the Audit Committee of the Board (the “Audit Committee”), approved the dismissal of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.”
Arcellx, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $63.1 million, net income $20.5 million.
“million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. Collaboration revenue: Collaboration revenue was $63.1 million and zero for the quarters ended December 31, 2023 and 2022, respectively. Collaboration revenue was $110.3 million and zero for the twelve months ended December 31, 2023 and”
Arcellx, Inc. entered into Assignment of Lease with a third party sublessee (effective 2024-01-30).
“On January 30, 2024, Arcellx, Inc. (the “Company”) entered into an Assignment of Lease (the “Assignment”) with a third party sublessee, pursuant to which the Company agreed to transfer and assign to a sublessee all of its rights, title, and interest under that certain Lease Agreement, dated October 5, 2018, between TFG West Watkins Property, LLC and the Company, as amended (the “Lease”).”
Arcellx, Inc. amended Amended Standstill Agreement with Gilead Sciences, Inc. (effective 2023-11-15).
“Arcellx also amended and restated its standstill and stock restriction agreement, dated December 8, 2022, with Gilead (as amended, the "Amended Standstill Agreement")”
Arcellx, Inc. entered into 2023 Purchase Agreement with Gilead Sciences, Inc. valued at $200 million (effective 2023-11-15).
“entered into a common stock purchase agreement (the "2023 Purchase Agreement") with Gilead Sciences, Inc. ("Gilead") on November 15, 2023, pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,242,542 shares of Arcellx's common stock (the "Shares") for an aggregate purchase price of $200 million”
Arcellx, Inc. amended License Amendment with Kite Pharma, Inc., a Gilead Company valued at $85 million (effective 2023-11-15).
“entered into an amendment (the "License Amendment") to its Collaboration and License Agreement with Kite Pharma, Inc., a Gilead Company ("Kite")”
Arcellx, Inc. reported third quarter ended September 30, 2023 results: revenue $15.0 million, net income Net loss was $39.3 million.
“million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026. Collaboration revenue: Collaboration revenue was $15.0 million and zero for the quarters ended September 30, 2023 and 2022, respectively. The revenue results for the three months ended September 30, 2023 is from the recognition of research”
Arcellx, Inc. reported second quarter ended June 30, 2023 results: revenue $14.3 million, net income $23.9 million.
“Collaboration revenue was $14.3 million and $0 for the quarters ended June 30, 2023 and 2022, respectively.”
Arcellx, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.
“The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain Broker Non-Votes 43,241,632 1,771 20,354 —”
Arcellx, Inc. shareholders approved Amendment to the Company's Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-13 meeting.
“The amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was approved based on the following results of voting: For Against Abstain Broker Non-Votes 40,536,934 939,717 8,162 1,778,944”
Arcellx, Inc. shareholders approved Election of Two Class I Directors at the 2023-06-13 meeting.
“The following nominees were re-elected by the holders of our common stock to serve as our Class I directors to hold office until our 2026 annual meeting of stockholders and until their successors have been duly elected and qualified: Nominee For Withhold Broker Non-Votes Ali Behbahani, M.D. 24,723,278 16,761,535 1,778,944 Derek Yoon 40,788,704 696,109 1,778,944”
Arcellx, Inc. entered into At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at $350,000,000 (effective 2023-05-08).
“On May 8, 2023, Arcellx, Inc. (the "Company") entered into an At-The-Market Equity Offering Sales Agreement (the "Agreement") with Stifel, Nicolaus & Company, Incorporated ("Stifel"), pursuant to which the Company may offer and sell, from time to time through Stifel, acting as its agent, or directly to Stifel, acting as principal, shares of the Company’s common stock, par value $0.001 per share. Pursuant to the sales agreement and related prospectus the Company can sell shares of its common stock having an aggregate offering price of up to $350,000,000 (the "Shares").”
Arcellx, Inc. reported the first quarter ended March 31, 2023 results: revenue $17.9 million, net income $27.3 million.
“First Quarter 2023 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 31, 2023, Arcellx had cash, cash equivalents, and marketable securities of $533.6 million. Arcellx expects that the cash, cash equivalents, and marketable securities on hand, will fund its operations through BLA filing of CART-ddBCMA planned for the first half of 2025 Collaboration revenue: Collaboration revenue was $17.9 million and zero for the quarters ended March 31, 2023 and 2022, respectively. The revenue results for the three months ended March 31, 2023 is from the recognition of research and development performed under the arrangement described in the recent license and collaboration agreement with Kite Pharma, Inc. (Kite). Revenue is being recognized on a percentage of completion basis over the term of the contract with Kite. R&D expenses: Research and development expenses were $32.9 million and $18.1 million for the quarters ended March 31, 2023 and 2022, respectively, an in”
Arcellx, Inc. reported fourth quarter and year ended December 31, 2022 results: net income Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188..
“Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2022.”
Arcellx, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting procedures, and other conforming updates effective immediately (effective 2022-12-15).
“On December 15, 2022, the Board of Directors (the “Board”) of Arcellx, Inc. (the “Company”) amended and restated the Company’s amended and restated bylaws, effective immediately.”
Arcellx, Inc. entered into Common Stock Purchase Agreement with Gilead Sciences, Inc. valued at $100 million (effective 2022-12-09).
“pursuant to which Arcellx agreed to issue and sell, and Gilead has agreed to purchase, 3,478,261 shares of Arcelllx’s common stock (the “Shares”) for an aggregate purchase price of $100 million”
Arcellx, Inc. entered into Collaboration Agreement with Kite Pharma, Inc., a Gilead Company valued at $225 million upfront cash payment (effective 2022-12-09).
“On December 9, 2022, Arcellx, Inc. (“Arcellx”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Kite Pharma, Inc., a Gilead Company (“Kite”)”
Arcellx, Inc. reported the fiscal quarter ended September 30, 2022 results: net income $92.9 million.
“Net loss was $92.9 million and $17.1 million for the quarters ended September 30, 2022 and 2021, respectively.”
Arcellx, Inc. reported that prior financial statements should not be relied upon.
“the Audit Committee of the Board of Directors of Arcellx, Inc., after discussion with management, concluded that (i) the Q1 2022 Financial Statements, included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “ SEC ”) on May 12, 2022, and (ii) the Q2 2022 Financial Statements included in the Quarterly Report on Form 10-Q filed with the SEC on August 15, 2022 should no longer be relied upon.”
Lance Thibault departed as interim Chief Financial Officer at Arcellx, Inc..
“On the Effective Date, Lance Thibault, who has served as the Company’s interim Chief Financial Officer since January 2022, will cease to be the interim Chief Financial Officer of the Company.”
Michelle Gilson was appointed as Chief Financial Officer at Arcellx, Inc..
“On May 20, 2022, Arcellx, Inc. (the “ Company ”) appointed Michelle Gilson as its Chief Financial Officer, effective May 23, 2022”
Olivia Ware was appointed as Director at Arcellx, Inc..
“On May 15, 2022 the Board appointed Olivia Ware to fill the vacancy on the Board, effective May 16, 2022, as a Class II director for a term that will expire at the annual meeting of stockholders to be held in 2024, subject to her earlier resignation, death or removal.”
Lewis T. Williams resigned as Director at Arcellx, Inc..
“Lewis T. Williams notified us that he intended to resign from the board of directors (the “Board”) of Arcellx, Inc. (the “Company”) and from the Board committees on which he serves.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.